| Wenting Li,Shiying Yu. Research progress on immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer. Oncol Transl Med, 2022, 8: 74-82. |
| 免疫检查点抑制剂在胃癌新辅助治疗中的研究进展 |
| Research progress on immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer |
| Received:January 13, 2022 Revised:April 20, 2022 |
| DOI：10.1007/s10330-022-0551-1 |
| 中文关键词: 胃癌 ；免疫检查点抑制剂 ；新辅助治疗 |
| 英文关键词: gastric cancer; immune checkpoint inhibitors (ICIs); neoadjuvant therapy |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Wenting Li | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | liwtpx@163.com | | Shiying Yu* | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | syyu@tjh.tjmu.edu.cn |
|
| Hits: 4552 |
| Download times: 5496 |
| 中文摘要: |
| 近年来，免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）已经成为晚期胃癌的重要治疗手段之一，免疫治疗在晚期胃癌中的应用已逐渐从后线前移至一线。与此同时，越来越多的研究者也开始关注免疫治疗能否用于可切除胃癌。目前ICIs在胃癌新辅助治疗的应用还在探索阶段，有多项临床试验正在开展中。已公布的研究结果显示ICIs在胃癌新辅助治疗中具有良好的应用前景。其中，SHARED研究42.1%的病理完全缓解率令人鼓舞。本文就ICIs在胃癌新辅助治疗中的研究进展和一些尚待解决的问题进行综述。 |
| 英文摘要: |
| In recent years, immune checkpoint inhibitors (ICIs) have become an important treatment strategy for
advanced gastric cancer. Immunotherapy has gradually transitioned from a later-line to a first-line treatment
for advanced gastric cancer. Simultaneously, more and more researchers have begun to pay attention
to whether immunotherapy can be used for resectable gastric cancer. The current use of ICIs in the
neoadjuvant treatment of gastric cancer is still in its exploratory stage, with a number of clinical trials
currently underway. However, the available data show good application prospects. This article reviews
the research progress on ICIs in the neoadjuvant therapy for gastric cancer and evokes some unresolved
problems. |
|
View Full Text
Download reader HTML全文 |
| Close |